✦ LIBER ✦

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

✍ Scribed by I.E. Smith; L. Biganzoli; H. Cortes-Funes; F. Franke; Y. Mostafa Kamel; J.Y. Pierga; K.I. Pritchard; D. Stroyakovs; C. Thomssen; J. Vinholes

Book ID: 118625727
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70885-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Efficacy and safety of bevacizumab in co

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

✍ Xavier Pivot; Andreas Schneeweiss; Shailendra Verma; Christoph Thomssen; José Lu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 531 KB

421 POSTER A phase I/II study of capecit

421 POSTER A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 505 KB